MedTrace Logo

Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome

NCT04850378 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2025-04-11

No results posted yet for this study

Summary

The study aims to describe the biochemical coagulation profile and investigate the effect of Low molecular weight heparin and Apixaban on this profile in patients with nephrotic syndrome.

Conditions

  • Nephrotic Syndrome
  • Thromboembolic Disease

Interventions

DRUG

Dalteparin

Drug: Dalteparin 200 units/kg once a day for 4-7 days.

DRUG

Apixaban

Drug: Apixaban 5 mg twice a day for 4-7 days.

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Sarah Kelddal, MD · Aarhus University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-25
Primary Completion
2024-05-01
Completion
2024-05-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04850378 on ClinicalTrials.gov